MNPR
NASDAQ HealthcareMonopar Therapeutics Inc. - Common Stock
Biotechnology
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
�� 市场数据
| 价格 | $108.52 |
|---|---|
| 成交量 | 192,891 |
| 市值 | 726.98M |
| 贝塔系数 | 1.480 |
| RSI（14日） | 73.8 超买 |
| 200日均线 | $70.13 |
| 50日均线 | $73.85 |
| 52周最高 | $112.57 |
| 52周最低 | $29.18 |
| Forward P/E | -34.59 |
| Price / Book | 5.27 |
🎯 投资策略评分
MNPR 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (88/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 MNPR in your text
粘贴任何文章、记录或帖子 — 工具将提取 MNPR 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.